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Abstract 
Introduction: The burden of type 2 diabetes is steadily increasing in low-and-middle-income countries, thereby pos-
ing a major threat from both a treatment, and funding standpoint. Although simulation modelling is generally relied 
upon for evaluating long-term costs and consequences associated with diabetes interventions, no recent article 
has reviewed the characteristics and capabilities of available models used in low-and-middle-income countries. We 
review the use of computer simulation modelling for the management of type 2 diabetes in low-and-middle-income 
countries.
Methods: A search for studies reporting computer simulation models of the natural history of individuals with type 2 
diabetes and/or decision models to evaluate the impact of treatment strategies on these populations was conducted 
in PubMed. Data were extracted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines and assessed using modelling checklists. Publications before the year 2000, from high-income 
countries, studies involving animals and analyses that did not use mathematical simulations were excluded. The full 
text of eligible articles was sourced and information about the intervention and population being modelled, type of 
modelling approach and the model structure was extracted.
Results: Of the 79 articles suitable for full text review, 44 studies met the inclusion criteria. All were cost-effective-
ness/utility studies with the majority being from the East Asia and Pacific region (n = 29). Of the included studies, 34 
(77.3%) evaluated the cost-effectiveness of pharmacological interventions and approximately 75% of all included 
studies used HbA1c as one of the treatment effects of the intervention. 32 (73%) of the publications were microsimu-
lation models, and 29 (66%) were state-transition models. Most of the studies utilised annual cycles (n = 29, 71%), and 
accounted for costs and outcomes over 20 years or more (n = 38, 86.4%).
Conclusions: While the use of simulation modelling in the management of type 2 diabetes has been steadily 
increasing in low-and-middle-income countries, there is an urgent need to invest in evaluating therapeutic and policy 
interventions related to type 2 diabetes in low-and-middle-income countries through simulation modelling, espe-
cially with local research data. Moreover, it is important to improve transparency and credibility in the reporting of 
input data underlying model-based economic analyses, and studies.
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Introduction
Type-2 Diabetes (T2D) has a rapidly increasing bur-
den across low-and-middle-income countries (LMICs) 
and is therefore a major healthcare concern from both 
Open Access
*Correspondence:  elton.mukonda@uct.ac.za
1 Division of Epidemiology and Biostatistics, School of Public Health 
and Family Medicine, Faculty of Health Sciences, University of Cape Town, 
Observatory, Cape Town 7925, South Africa
Full list of author information is available at the end of the article
Page 2 of 10Mukonda et al. BMC Health Services Research         (2021) 21:1313 
a treatment and a funding perspective [1]. The Interna-
tional Diabetes Federation (IDF) [2] indicates that dia-
betes affected 463 million people worldwide in 2019, of 
which about 90% was attributable to T2D, and up to 80% 
of people living with diabetes come from LMICs [2, 3]. 
The IDF also estimates that the number of people liv-
ing with diabetes will grow to 700 million by 2045, with 
the greatest increase in prevalence expected to occur 
in Africa, the Middle East, South-East Asia and Central 
America [2]. Diabetes-related mortality accounted for up 
to 11% of all-cause mortality among people aged 20-79 in 
2019 [2], while the 2017 Global Burden of Disease study 
identified diabetes as the fourth leading cause of disabil-
ity [4].
In addition to morbidity and mortality, diabetes causes 
substantial economic burden for individuals, society, 
and health systems [5–7]. In 2019, diabetes-related 
health expenditure was estimated to be US$760 billion 
[2]. While high income countries (HICs) accounted for 
a large proportion of this amount (90%), the significant 
increases in disease prevalence expected in LMICs mean 
they will likely carry a large proportion of future global 
diabetes health expenditure [2, 4]. Given that healthcare 
systems and the available (limited) resources are, for the 
most part, directed towards communicable disease man-
agement in LMICs [8], it is imperative that effective and 
cost-effective interventions are identified to reduce the 
current and future diabetes burden.
The long-term nature of chronic and progressive dis-
eases like T2D lends itself to the use of simulation mod-
elling. Simulation modelling is increasingly being used 
to help inform decisions on the allocation of scarce 
resources and to evaluate the clinical and economic out-
comes associated with new public health interventions or 
clinical treatment strategies [9, 10].
Key features of T2D modelling
For T2D, there have been numerous modelling studies 
that have been conducted, investigating both pharma-
cological and non-pharmacological strategies for disease 
prevention and management. These studies estimate the 
costs and benefits across a target population by consid-
ering the outcomes of a group of patients (simulation 
cohort) that is designed to be representative of the target 
population [11]. In terms of simulation approach, out-
comes can be estimated for each individual then averaged 
across a sufficiently large sample (known as patient-level/
microsimulation modelling) or are estimated for a group 
of individuals without considering the outcomes of indi-
viduals in the cohort (known as cohort modelling). Most 
of the studies make use of Markov-based models using 
either cohort/microsimulation solution methods, dis-
crete-time microsimulation models or discrete-event 
microsimulation models to estimate the costs and health 
benefits of the simulation.
Markov-based models are state-transition models that 
assess the probabilities of transition to determine if a 
patient has moved from one state to another at the end 
of each cycle, with transition to another state relying 
solely on the current state [12]. Like the Markov-based 
models, discrete-time microsimulations model disease 
progression through time using a constant time step and 
then assess which events have happened at the end of 
each time step (or cycle). However, the main difference 
is that each complication is often modelled as a single 
event and the events are not mutually exclusive. On the 
other hand, for discrete-event microsimulations, move-
ments between patients’ health states are usually driven 
by events which may occur at varying times (rather than 
during cycles of fixed length), and time-to-event dis-
tributions are required for each event [13]. Other less 
common modelling approaches include continuous time 
models (using differential equations) and object-oriented 
simulations.
Another key feature of model-based T2D studies is 
how they assess the robustness of model outputs to input 
parameter uncertainty (second-order uncertainty). This 
is often done through deterministic sensitivity analy-
sis, where model inputs are specified as multiple point 
estimates and varied manually, or through probabilis-
tic sensitivity analysis where rather than being treated 
as fixed values, model inputs are specified as probabil-
ity distributions and varied stochastically to provide a 
probabilistic distribution of model output values. Monte 
Carlo simulation techniques are often employed to per-
form probabilistic sensitivity analysis on both cohort or 
microsimulation models and are also used to account for 
patient heterogeneity and stochastic uncertainty (first-
order uncertainty).
T2D modelling in LMICs
Most model-based studies on T2D are conducted in HICs 
and generalised to LMICs, which is not entirely justified 
given how sub-phenotypes and clinical consequences 
of T2D vary by ethnic groups (for example, Asians and 
Africans develop diabetes a decade earlier and at a lower 
body mass index than those with European ethnicity [14, 
15]). While attempts have been made to compile the evi-
dence base and appraise the methodological quality of 
simulation models and model-based economic evalu-
ations [1, 10, 16–19], no review has been identified that 
focuses solely on LMICs. We reviewed the use of simu-
lation models and model-based economic evaluations in 
populations with T2D. The specific objectives were the 
following:
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1. To identify model-based studies on T2D popula-
tions investigating both pharmacological and non-
pharmacological strategies for T2D management in 
LMICs.
2. To assess whether all key elements of the modelling 
procedure were clearly reported according to the 
Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS) checklist [20].
3. To summarize and assess the quality and validity of 
simulation models used in LMICs and discuss knowl-
edge gaps, challenges, and opportunities.
Materials and methods
Peer-reviewed studies that reported computer simulation 
models of the natural history of individuals with Type 2 
diabetes or used decision models to evaluate the impact 
of interventions on these populations were identified 
for this study. Searches were conducted in PubMed (29 
June 2020) and followed the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines [21]. Exact search terms and search strategy 
are included as supplementary material.
The inclusion/exclusion criteria for study selection are 
provided in Table  1. Briefly, studies were restricted to 
those published in the English language since 2000, while 
only studies from countries classified as low and mid-
dle income by the World Bank (2020 classification) were 
extracted [22]. Studies were excluded from the review 
if they were clinical, costing or cost-effectiveness/util-
ity studies with no modelling. Given the shorter time 
frames for within-trial cost effectiveness analyses, these 
were also excluded. Further, studies where costs and 
outcomes were calculated for a period less than 5 years 
were also excluded as most T2D related health problems 
develop gradually over several years. Additionally, studies 
focusing on screening for, or preventing T2D rather than 
post-diagnosis costs and outcomes were excluded.
Data on the study setting, intervention type, cost per-
spective, model type and structures, simulation approach, 
disease progression, handling of uncertainty, incorpora-
tion of treatment effect and outcomes were extracted to 
give an overview of the model- based studies included in 
the review. The model structure must have included the 
progression of T2D (or specific complications) and some 
health economic outcome, including (but not restricted 
to) costs, quality-adjusted life-years (QALYs), disability-
adjusted life-years (DALYs), life-years (LYs) and incre-
mental cost-effectiveness ratios (ICERs). Studies were 
then assessed using the Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS) [20] check-
list for economic evaluation of health interventions, 
which assesses whether all key elements of model struc-




The search identified 2882 citations, excluding any dupli-
cate publications and studies from high income countries 
(Fig. 1). During the screening of titles and abstracts, a fur-
ther 2803 citations were excluded. Upon full text assess-
ment of the remaining 79 articles, 44 studies met criteria 
for inclusion. A summary of the study setting, the model 
structure, simulation approach, complications modelled, 
the disease progression modelling approach and the 
handling of uncertainty is provided in Supplementary 
Table 1. Additional information on the intervention type, 
cost perspective, treatment effects, model outcomes and 
data sources is provided in Supplementary Table  2. Of 
the included studies, 21 (52.3%) were from China while 
6(13.6%) were multiple country publications. A majority 
Table 1 Inclusion and exclusion criteria for the review
Parameter Inclusion criteria Exclusion criteria
Patient population Patients with T2DM Patients with T1D, Gestational diabetes, 
Healthy individuals, pre-diabetes
Interventions Modelling studies assessing any pharmacological or non-pharmacological
intervention for the treatment of T2D
Study design Cost-effectiveness analyses
Cost-utility analyses
Within trial Cost-effectiveness analyses,
Within trial Cost-utility analyses
Microsimulations, cohort models
Modelling application studies with a time horizon of ≥5 years Modelling application studies with a 
time horizon of < 5 years
Country Low-and-middle income countries High income countries
Language Published material in English Published material not in English
Time frame Evidence published since 2000 to 30 June 2020 Evidence published prior to 2000
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of the studies (n = 29, 65.9%) were exclusively from the 
East Asia and the Pacific region while 7(15.9%) were 
from Latin America and the Caribbean (Fig. 2). Only two 
of the studies, one of which is a multiple country study, 
included Sub-Saharan African populations (n = 2, 4.5%).
All of the 44 studies were cost-effectiveness/utility 
analyses with 34 (77.3%) evaluating the cost-effectiveness 
of pharmacological interventions, 4 (9.1%) for obesity 
surgery and 4 (9.1%) evaluating multiple intervention 
types. More than half of the studies (n = 26, 60.5%) pre-
sented results from the healthcare provider perspective, 
while the rest presented results from the healthcare payer 
perspective (n = 13, 30.2%), and the societal perspective 
(n = 4, 9.1%). In all, 40 studies (90.9%) reported all key 
elements mentioned in the CHEERS checklist, although 
only a few studies (n = 3, 6.5%) provided the completed 
checklist as part of the supplementary material.
Key model characteristics
Of the identified 44 publications, 29(65.9%) of the mod-
els were “Markov based” while 15(34.1%) were based on 
discrete-time microsimulations. In all, 12 (27.3%) of the 
publications made use of cohort models which estimated 
the outcomes for the group of patients without explic-
itly considering the outcomes of each individual patient, 
while the rest employed patient-level/microsimulation 
solution approaches.
Most of the studies (n = 42, 95.5%) simulated multi-
ple micro-vascular or macro-vascular complications 
related to type 2 diabetes (Supplementary Table 1), with 
33(75.0%) of the studies modelling both micro-vascular 
and macro-vascular complications. Micro-vascular com-
plications included diabetic nephropathy, neuropathy, 
and retinopathy while macro-vascular complications 
included myocardial infarction, coronary artery disease, 
peripheral arterial disease and stroke. As these complica-
tions may take many years to develop, they are often esti-
mated using short-term proxy outcomes, such as glycated 
haemoglobin levels (HbA1c) [18]. For most of the studies, 
the impact of the interventions was simulated through 
changes in risk factors, particularly HbA1c, which was 
used in 33(75.0%) of the studies. Other risk factors 
included body mass index (BMI)/weight, hypoglycaemic 
events, lipid levels and blood pressure. The change in the 
Fig. 1 PRISMA diagram showing the flow of publications included and excluded from the review
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risk factors subsequently informed the risk of onset of the 
complications.
Movement between health states depends on the sim-
ulation method adopted in the study. In the included 
studies, 27(61.4%) made use of transition probabilities to 
simulate disease progression, while 15(34.1%) made use 
of risk equations, and 2(4.5%) studies used a combination 
of transition probabilities (for microvascular complica-
tions) and risk equations (for macrovascular complica-
tions). The risk equations used were the United Kingdom 
Prospective Diabetes Study (UKPDS) risk equations 
(n = 14, 31.8%) [23–25], and the Risk Equations for Com-
plications Of type 2 Diabetes (RECODe) (n = 4, 9.1%) 
[26]. The majority of the studies assessed the probabili-
ties of moving to another state (Markov models) or the 
occurrence of events (discrete-time simulations) through 
1-year cycles (n = 29, 70.7%), and accounted for costs and 
outcomes over 20 years or more (n = 38, 86.4%).
More than half of the studies (n = 29, 65.9%) made 
use of seven existing validated diabetes models. These 
validated models included the IQVIA CORE Diabe-
tes Model, formerly known as the IMS CORE Diabetes 
Model (n = 12, 27.3%), Cardiff Diabetes Model (n = 7, 
15.9%), Chinese Outcomes Model for T2DM (n = 4, 
9.1%) and the UKPDS Outcomes Model (n = 2, 4.5%) 
[27–30]. All the studies that used existing models pro-
vided short descriptive summaries of the model. These 
models all went through internal validation to ensure the 
model accurately predicts outcomes from the same tri-
als and datasets from which they were originally devel-
oped. Additionally, 6 of the 7 models, corresponding to 
28(63.6%) studies, reported external validation which 
compares a model’s results with that of real-world results 
that were not used to populate the model (e.g., other 
clinical trials). This is done in order to ensure predictive 
validity and accuracy.
Handling uncertainty
Sensitivity analyses such as the impact of discount rates, 
time horizons, intervention efficacy and intervention 
costs were frequently reported. Univariate sensitivity 
analyses were performed and reported in all but one of 
the studies included in this review. Most of the studies 
(n = 41, 93.1%) also performed probabilistic sensitivity 
analysis, through Monte-Carlo simulation though it is 
Fig. 2 The number of studies in a year by region
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not always clear whether first- or second-order uncer-
tainties were considered in the simulations.
Outcomes and costs
The most reported outcomes were QALYs (n = 41, 93.1%) 
and life years (n = 2, 4.5%). All the studies reported direct 
costs and also ICERs as a summary measure of costs and 
outcomes. Other reported outcomes were DALYs and 
cumulative incidence of complications, while 4(9.1%) of 
the studies accounted for indirect costs.
Key data sources
Data on the effectiveness of interventions were mainly 
obtained from literature searches (n = 29, 65.9%), and 
from observational studies (n = 9, 20.5%), but most 
resource-use data and unit costs were obtained through 
routine data collection from administrative databases 
and published price lists (n = 30, 65.2%). The majority of 
the studies made use of utility or health related quality of 
life data obtained from literature reviews (n = 35, 87.5%), 
while baseline patient characteristics of the simulated 
cohorts including age, sex, duration of diabetes, race/
ethnicity, and other modifiable risk factors/biomarkers 
related to T2D, were often based on RCTs or literature 
reviews (n = 31, 70.5%). The sources of the data used to 
model the progression of microvascular and/or mac-
rovascular complications varied. The validated models 
made use of data from RCTs with the most commonly 
used RCT being the UKPDS and the Diabetes Control 
and Complications Trial (DCCT) [31–33]. The other 
studies made use of literature reviews to obtain inputs 
used to define population characteristics and transition 
probabilities. There was no mention, however, of whether 
meta-analysis had been used to pool estimates from the 
studies that were retrieved from the literature.
Discussion
Given the high cost and burden of diabetes, there is 
significant interest in identifying strategies that are 
cost-effective and delay the onset of T2D related com-
plications. The long-term nature of T2D necessitates the 
use of simulation modelling in order to extrapolate from 
short-term empirical studies to predict costs and health 
benefits over the lifetime of an individual. The current 
study aimed to critically appraise the use of simulation 
modelling for long-term T2D management in LMICs. 
The studies identified were assessed for their techni-
cal characteristics while the model-based economic 
evaluations were additionally assessed for their adher-
ence to reporting standards. Overall, there has been an 
increase in the number of modelling studies conducted 
in LMICs, particularly in Asia, with most of the studies 
being model-based economic evaluations of pharmaco-
logical interventions. The paucity of studies exclusively 
from Africa is somewhat indicative of the focus on com-
municable disease research in the region [34]. This is 
worrisome given the expected increase in T2D preva-
lence and highlights the need for more T2D research in 
the region. Most of the economic evaluations adhered 
to reporting standards (CHEERS) which is crucial given 
the push for more transparent reporting of T2D mod-
els and economic evaluations to improve reliability and 
reproducibility [35]. Despite this, there are key issues that 
modellers in LMIC populations need to account for.
While most of the studies identified in this review 
employed state transition (Markov) modelling techniques 
(Supplementary Table 1), there is no clear consensus on 
the most appropriate modelling approach [18]. A defining 
feature of Markov modelling, which is also a limitation, 
is the ‘memoryless property’ or ‘Markovian assumption’ 
where future transitions are not dependent on previous 
states [12]. There are ways of mimicking memory for 
cohort models such as the introduction of tunnel states, 
which in turn can lead to state explosion thereby mak-
ing the model difficult to manage [36, 37]. Willis et  al. 
[37] also identified potentially biased estimates of the 
incremental cost-effectiveness ratio (ICER) arising from 
“uncaptured” patient heterogeneity as a key shortcoming 
of using cohort models in cost-effectiveness analyses. For 
T2D, this additional complexity is inevitable given the 
significant heterogeneity existing between patients and 
the interrelated risks [10].
In contrast with Markov-based cohort models, 
Markov-based microsimulation models simulate indi-
vidual patient histories over time, thereby automatically 
accounting for heterogeneity. Additionally, the Markov 
assumption is overcome by assigning attributes to indi-
viduals that can influence their progression through the 
model (tracker variables), but which can also be used to 
update the risk of future events accordingly [38, 39]. A 
more flexible alternative to Markov modelling identified 
in this review is discrete-time microsimulation model-
ling. This approach accounts for an individual’s specific 
demographic characteristics, risk factors and event his-
tory when assigning risks of events/complications occur-
ring and is not restricted to fixed ‘mutually exclusive’ 
health states as is the case for Markov-based models [40, 
41].
There are drawbacks to microsimulation modelling, 
particularly, the onerous computational and data require-
ments [10]. In LMICs, national (and ethnic)-specific 
data with which to develop T2D microsimulation mod-
els are seldom available [42]. As a result, most studies 
investigating the long-term health outcomes and eco-
nomic consequences of interventions either make use of 
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existing validated diabetes models or use international 
RCT data to develop the models despite the possible 
transferability issues [42]. In this study, we identified 7 
existing validated models; IMS (IQVIA) CORE Diabe-
tes Model, Cardiff Diabetes model, Chinese Outcomes 
Model for T2D (COMT), UKPDS Outcomes Model 
(UKPDS OM), CDC-RTI model, Economic and Health 
Outcomes (ECHO) model and the Januvia Diabetes Eco-
nomic (JADE) model [27–30, 43–45]. Of these models, 
only one was a Markov-based cohort model (CDC-RTI) 
with the rest being either discrete-time microsimulations 
(JADE, UKPDS OM, COMT, Cardiff) or Markov-based 
microsimulations (CORE, ECHO). It is worth noting that 
of these models, only one was developed in a low- and 
middle-income country. While many of these models had 
undergone external validation, it was not always clear, 
however, whether the models had been validated for the 
populations of interest.
Previous reviews by Tarride et al., Yi et al., Govan et al., 
Charokopou et al., and Li et al. have critically appraised 
the above models, provided comprehensive summaries, 
and discussed the capabilities and shortcomings of the 
models [1, 10, 16–19]. They found that the structures of 
the Markov-based microsimulation models were broadly 
similar, as were the discrete-time microsimulation mod-
els. For the Markov-based microsimulations, each com-
plication was included as a sub-model although the 
number of health states differed by model. As an example, 
the nephropathy sub-model in the IMS (IQVIA) CORE 
Diabetes Model had 7 states while the nephropathy sub-
model in the Economic and Health Outcomes (ECHO) 
model had 4 states. The discrete-time microsimulation 
models, on the other hand, are based on a series of risk 
equations. In principle, risk equations predict the annual 
probability of specific micro/macro-vascular end points 
based on patient demographics, duration of diabetes, risk 
factor levels, and history of micro/macro-vascular com-
plications, and then employ Monte Carlo methods to 
predict the occurrence of long-term complications.
For most of the validated models, data from the UKPDS 
were used to derive the risk equations or determine 
transition probabilities that predict the long term T2D 
complications [1, 16]. Tarride et  al. [1] highlight some 
issues associated with using UKPDS data. First, there 
is an issue of generalizability to more ethnically diverse 
populations and different ethnic groups given how 83% 
of the UKPDS participants had European ethnicity with 
a median age of 54 years (IQR 48–60 years) [31]. Second, 
there is a likelihood that treatment regimes evaluated in 
the study may not correspond to current practice [1, 46]. 
Further, exposure to risk factors, disease incidence, and 
standards of care for T2D are also likely to be notably 
different now compared to when the original study was 
conducted (1977-1997). This may affect the applicability 
of most validated T2D models to different LMIC popu-
lations. In addition, to use a validated T2D model, it is 
often assumed that the overall predicted rate of events 
is applicable to a similar population as the one used for 
model development or external validation. This, however, 
is not always the case considering there are notable dif-
ferences in the proportion of baseline risk factors such as 
demographic, ethnic, lifestyle, and treatment options in 
different regions.
Strategies for modifying existing models have been 
proposed for use in populations with dissimilar charac-
teristics to the ones from which the models were derived, 
and where the appropriate data and resources to develop 
new models are not available. The aim is to improve the 
performance of risk prediction models which may over- 
or under-estimate risk in different populations [47]. 
One such strategy is recalibration of the underlying risk 
equations or transition probabilities using local data 
on risk factor distributions and the incidence of micro/
macro-vascular complications [48]. The strategy assumes 
that the associations between different risk factors and 
complications are constant, hence adjusting the equa-
tions for different risk factor distributions and different 
background incidence of micro/macro-vascular com-
plications is adequate [48]. Of the studies that made use 
of existing validated models, 4 of them used a model, 
the Chinese Outcomes Model for T2DM (COMT) [29] 
whose underlying risk equations had been recalibrated 
using Chinese-specific epidemiological data. Specifically, 
the Risk Equations for Complications of Type 2 Diabetes 
(RECODe), which were developed for the United States 
population, were recalibrated to suit the Chinese popu-
lation by “adding an adjustment regulator to the original 
linear predictor within the risk equations” with a view to 
eliminating the over- or under-estimation of risk in the 
Chinese population [29, 49].
While recalibration of Markov-based models is not as 
common, guidance from the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) 
suggests that adaptation of previously published or vali-
dated models for “local” use is possible [50]. According to 
Mullins et al. [50], key to the adaptation process is the use 
of country/region specific epidemiologic data to adjust 
the baseline characteristics of the simulated cohort, pos-
sibly generate new transition probabilities and adjust the 
initial distributions for Markov-based models. Further, 
local cost, health state preferences and utilities data are 
also important for the adaptation.
When either developing a new model or adapting/
recalibrating an existing one, the availability of reli-
able and applicable data is key. The scarcity of robust 
T2D data from LMIC populations continues to be a 
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major hindrance in conducting model-based analy-
ses that focuses on these populations [42, 46]. There 
are other data requirements for model-based analy-
ses which include baseline patient characteristics of 
the simulated cohort, clinical effectiveness data, utility 
data and resource use (cost) data. Two main strategies 
are employed to get these data: collecting existing data 
through systematic literature reviews and meta-analyses, 
or collecting the data in a clinical trial [42]. Other pos-
sible sources include observational studies, routine data 
collection and expert review. Baik et  al. [42] advocate 
for increased use of observational study data on T2D in 
LMICs despite potential selection bias issues when com-
pared to RCTs. Specifically, they highlight how param-
eters such as health-related quality of life, and resource 
use are less likely to be subject to selection bias if derived 
from observational studies. Considering this, observa-
tional studies, which are more readily available in LMICs, 
can bridge the gaps in data required for economic evalua-
tions and model-based analyses.
Strengths and limitations
Despite being the first to provide a snapshot of T2D 
modelling in LMICs and a synthesis of key considerations 
in the design and development of T2D simulation mod-
els in LMICs, this review is not without limitations. First, 
by extracting only the information related to modelling, 
valuable insights on the efficacy and cost-effectiveness 
of the interventions being modelled are missed. A more 
comprehensive evaluation of these studies in relation to 
the actual decision problem being addressed and iden-
tifying the most cost-effective interventions would be 
possible in future. Second, the exclusion criteria such as 
omitting published material not in English or excluding 
studies on prevention of or screening for T2D may have 
omitted some studies that would have added to the dis-
course. Lastly, a more appropriate checklist for input data 
reporting in T2D model-based analyses is the recently 
developed Diabetes Modelling Input Checklist [35]. 
However, considering the significant overlap with the 
CHEERS checklist and how most studies in our review 
were published before it was developed, the CHEERS 
checklist was deemed adequate for the task. Despite 
these shortcomings, we believe that no major studies that 
can change the results of this review have been missed.
Conclusions
In summary, the use of simulation modelling in the man-
agement of T2D has been steadily increasing in LMICs, 
possibly allowing improved decision making on the opti-
mal allocation of scarce resources and the improvement 
of patient outcomes. Nevertheless, there is an urgent 
need to invest in evaluating therapeutic and policy 
interventions related to T2D in LMICs through simula-
tion modelling, especially with local research data. In 
addition, clinical and observational research on T2D 
in LMICs is clearly warranted, particularly among sub-
Saharan African populations given the paucity of model-
based analyses in the region. Finally, it is important to 
improve transparency and credibility in the reporting of 
input data underlying model-based economic analyses, 
and modelling studies, respectively, in LMICs. The use of 
the Diabetes Modelling Input checklist and the CHEERS 
checklist is therefore encouraged.
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